Merck's (MRK) KEYTRUDA sBLA in NSCLC Accepted for FDA Priority Review
Tweet Send to a Friend
Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
